UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Amicus Therapeutics
In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Amicus Therapeutics (NASDAQ: FOLD), and slightly raised its price target from $10.00 to $11.00.
Canaccord noted, “We think Q3 pivotal migalastat Fabry monoTx '011 trial data will be a strong positive catalyst and that the trial has a high chance of success. We also expect positive full Ph2 AT2220/ERT Pompe combo data in Q3/12. Our $11 target is based on a pNPV analysis.”
Amicus Therapeutics closed on Tuesday at $6.02.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.